Esperion Therapeutics Inc. has reiterated its financial outlook for the full year 2025, expecting operating expenses to range between $215 million and $235 million, which includes approximately $15 million in non-cash stock compensation expenses. The company reported robust third quarter results, with total revenue for Q3 2025 increasing 69% year-over-year to $87.3 million, and U.S. net product revenue growing 31% year-over-year to $40.7 million. Esperion highlighted strong commercial momentum and expanded payer coverage, reaching over 90% of commercial lives and more than 80% of Medicare lives. The company expects to achieve sustainable profitability beginning in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570018-en) on November 06, 2025, and is solely responsible for the information contained therein.